文献速递头颈与中枢神经肿瘤骨软组织肉瘤与黑色素瘤

黑色素瘤脑转移全身治疗进展

Advances in the systemic treatment of melanoma brain metastases.
PubMed 文献 · Ann Oncol · 2018-01-01

本综述聚焦黑色素瘤脑转移(MBM)全身治疗。BRAF联合MEK抑制颅内缓解率近60%,免疫检查点抑制剂尤其是联合治疗可见高比例持久颅内缓解,立体定向放疗与全身治疗联合安全有效,MRI新技术助力疗效评估。

要点

  • BRAF+MEK抑制治疗MBM颅内缓解率接近60%
  • 免疫联合治疗在MBM中可见高比例持久颅内缓解
  • 立体定向放疗联合全身治疗安全有效

核心结论

  • 靶向治疗和免疫治疗进展为MBM治疗带来乐观前景,联合治疗可提高颅内缓解率。

研究设计与样本

  • 综述评估已发表证据,描述MBM为多层面疾病并概述现有和研究性治疗。

主要发现

  • BRAF抑制联合MEK抑制治疗MBM的颅内缓解率接近60%。
  • 免疫检查点抑制剂在MBM中可能有效,联合治疗观察到高比例持久颅内缓解。
  • 立体定向放疗与全身治疗联合安全有效。
  • MRI能力演进启发了肿瘤负荷和疗效评估新方法。

关键数值与推荐

  • BRAF+MEK抑制治疗MBM颅内缓解率接近60%。

临床怎么用

  • MBM患者可考虑BRAF+MEK抑制或免疫联合治疗,并联合立体定向放疗。

局限性

  • MBM患者通常被排除在临床试验外,导致该人群全身治疗数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Of the solid tumor types that metastasize to the brain, melanoma has the highest propensity to form brain metastases. In addition, much remains unknown regarding the pathophysiology involved in melanoma cell extravasation through the blood-brain barrier, which enables interactions with the microenvironment, and melanoma cell transcriptomic responses to brain-specific cues. However, recent developments in targeted therapy and immunotherapy have generated considerable optimism regarding the treatment of metastatic melanoma. Although robust efficacy data exist on systemic therapy treatment of extracranial melanoma, data in the setting of melanoma brain metastases (MBM) are limited, primarily because patients with MBM are typically excluded from clinical trials. However, several clinical trials focusing on patients with MBM are now complete, and more are underway. Clinical evaluation of serine/threonine-protein kinase B-Raf inhibition in combination with MEK inhibition for MBM produced intracranial response rates of close to 60%, suggesting that inhibition of the mitogen-activated protein kinase pathway has the potential to further improve MBM outcomes. For immunotherapy, there is now increasing evidence that checkpoint inhibitors may also be effective in MBM with a high rate of durable intracranial responses observed with combination therapy. Furthermore, radiotherapy-particularly MBM treatment with mainstay stereotactic radiosurgery-appears to be safe and effective when combined with systemic therapy. Finally, evolving magnetic resonance imaging capabilities have inspired new approaches to the measurement of tumor burden and treatment responses. This review evaluates current published evidence describing MBM as a multifaceted disease and presents an overview of currently available and investigational treatments for patients with MBM.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Glitza Oliva IC, Schvartsman G, Tawbi H, et al. Advances in the systemic treatment of melanoma brain metastases. Ann Oncol. 2018. PMID: 29790899. doi:10.1093/annonc/mdy185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。